Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Probenecid, Drug Evaluation, Drug Interactions, Acquired Immunodeficiency Syndrome, Zidovudine
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Interferon. Aerosolized pentamidine for Pneumocystis carinii pneumonia (PCP) prophylaxis. Concurrent Treatment: Allowed: Radiation for skin lesions. Patients with symptomatic HIV infection taking zidovudine (AZT) five or six times a day as therapy. Includes patients with AIDS who have history of cytologically confirmed Pneumocystis carinii pneumonia (PCP), patients with advanced AIDS related complex (ARC), and HIV antibody positive patients. Patients must be able to give written informed consent. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: Allergy to probenecid. Any underlying medical condition sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy. History of urinary tract urate stones or gout. Becoming acutely ill, unstable, or febrile. Concurrent Medication: Excluded: Methotrexate. Antiretroviral drugs. Ganciclovir. Amphotericin. Experimental drugs. Isoniazid. Pyrazinamide. Flucytosine. Intravenous pentamidine. Dapsone. Fansidar. Antineoplastic drugs not specifically allowed. Trimethoprim / sulfamethoxazole. Valproic acid. Opiates. Rifampin. Sulfonylureas. Concurrent Treatment: Excluded: Radiation not specifically allowed. Patients with the following are excluded: Allergy to probenecid. Any underlying medical condition sufficient, in investigator's opinion, to prevent adequate compliance with study therapy. History of urinary tract urate stones or gout. Becoming acutely ill, unstable, or febrile.
Sites / Locations
- UCD Med Ctr
- Johns Hopkins Hosp